Drug intelligence / Profile preview

Technetium Tc-99m disofenin

Development stage
Discontinued
Lead developer
Pharmalucence
Modality
Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

Technetium Tc-99m disofenin is a radiopharmaceutical diagnostic agent used primarily for hepatobiliary imaging. It is administered intravenously and enables visualization of the liver, gallbladder, and bile ducts to assess their function and detect anatomical changes. The compound consists of the radioisotope technetium Tc-99m complexed with disofenin, an iminodiacetic acid derivative. Disofenin facilitates hepatic uptake due to its high liver-to-kidney extraction ratio and reduced dependence on serum bilirubin levels compared to other tracers in its class. Technetium Tc-99m decays by isomeric transition with a physical half-life of about 6 hours; after administration, it is rapidly cleared from circulation via the hepatobiliary system. The primary clinical indication for this agent has been in diagnosing acute cholecystitis and evaluating suspected biliary tract disease[1][2][3][4][5]. **Developer:** Pharmalucence **Mechanism of Action:** Hepatic uptake for diagnostic imaging of the hepatobiliary system.

Brand names
Hepatolite
Other names
Tc-99m disofeninTc99m disofeninTc 99m disofenintechnetium Tc 99M disofenin
02

Targets

OATP1B1 (Organic anion transporting polypeptide 1B1)

Beyond the preview

Go deeper on Technetium Tc-99m disofenin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Technetium Tc-99m disofenin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call